Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

Boston Scientific CorporationTrade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Charles Schwab Corporation Common Stock — how do they compare? Boston Scientific Corporation trades at $51 (market cap $74.19B), while Charles Schwab Corporation Common Stock trades at $108.14 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 2.5× Boston Scientific Corporation's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXSCHW
Market Cap
$74.19B$186.25B
Sector
HealthFinancials
52-Week High
$108.14$108.02
52-Week Low
$42.63$85.35
Enterprise Value
$86.27B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.

Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $107.99, up 0.36% today, near its all-time high. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels suggest overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.56 expected, and revenue growth accelerated to $23.92 billion in 2025. Analyst sentiment remains positive with a 56.87% buy rating and a $122.33 consensus price target, indicating potential upside.

The outlook for SCHW is favorable given robust earnings performance and upward revenue guidance, but risks include potential market volatility from economic data and ongoing litigation. Institutional buying and a high ROE of 22.45% support the bullish case, though investors should monitor inflation reports and insider selling activity for near-term cues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW